Figures & data
Table 1. Intravenous dosing regimen of iron isomaltoside in IBD patients with iron deficiency anaemia.
Table 2. Baseline demographics by infusion regime of intravenous iron isomaltoside.
Figure 1. Changes from baseline in haemoglobin, s-ferritin, transferrin saturation and reticulocyte concentration over time in patients treated with 1500–2000 mg iron isomaltoside (group A) and 2500–3000 mg iron isomaltoside (group B). Least square means (95% CIs) are derived from a repeated measures mixed model with treatment and week as factors and baseline value as covariate. *p < 0.05, **p < 0.01, ***p < 0.001 (test for difference from baseline value).
![Figure 1. Changes from baseline in haemoglobin, s-ferritin, transferrin saturation and reticulocyte concentration over time in patients treated with 1500–2000 mg iron isomaltoside (group A) and 2500–3000 mg iron isomaltoside (group B). Least square means (95% CIs) are derived from a repeated measures mixed model with treatment and week as factors and baseline value as covariate. *p < 0.05, **p < 0.01, ***p < 0.001 (test for difference from baseline value).](/cms/asset/3556d062-58f5-437d-81d1-ef9ea84755b9/igas_a_1196496_f0001_c.jpg)